Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Deffered Revenue (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 83.82% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 83.82% year-over-year, with the annual reading at $2.0 million for FY2025, 83.82% down from the prior year.
  • Non-Current Deffered Revenue hit $2.0 million in Q4 2025 for Sutro Biopharma, down from $3.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $90.0 million in Q2 2022 to a low of $145000.0 in Q3 2021.
  • Historically, Non-Current Deffered Revenue has averaged $37.6 million across 5 years, with a median of $19.8 million in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 84.19% in 2021 and later soared 51439.31% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $145000.0 in 2021, then skyrocketed by 61889.66% to $89.9 million in 2022, then crashed by 40.61% to $53.4 million in 2023, then tumbled by 76.52% to $12.5 million in 2024, then plummeted by 83.82% to $2.0 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for STRO at $2.0 million in Q4 2025, $3.8 million in Q3 2025, and $6.9 million in Q2 2025.